CUE - CIK 0001645460
The table below shows Cue Biopharma, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $16.38M | $11.70M | $27.49M | $13.14M | $32.42M | $30.03M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $5.35M | $387.00K | $532.00K | $0.00 | $3.15M | $1.85M |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $26.39M |
| $25.82M |
| $30.84M |
| $15.93M |
| $37.26M |
| $33.90M |
| Property, plant & equipment | $288.00K | $307.00K | $454.00K | $523.00K | $570.00K | $667.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $30.88M | $31.64M | $40.71M | $22.25M | $44.81M | $42.33M |
| Accounts payable | $3.33M | $2.35M | $3.63M | $3.78M | $6.47M | $3.91M |
| Total current liabilities | $7.39M | $15.52M | $19.25M | $15.50M | $16.79M | $16.46M |
| Long-term debt | - | - | - | - | $1.33M | $2.29M |
| Total liabilities | $9.27M | $18.40M | $22.55M | $15.67M | $19.44M | $20.71M |
| Retained earnings | -$373.64M | -$370.05M | -$362.60M | -$354.12M | -$332.37M | -$323.71M |
| Total equity | $21.61M | $13.25M | $18.16M | $6.58M | $25.37M | $21.62M |